Phase 3 Recruiting Academic/Other
This phase III trial compares stereotactic body radiation therapy (SBRT), (five treatments over two weeks using a higher dose per treatment) to usual radiation therapy (20 to 45 treatments over 4 to 9 weeks) for the treatment of high-risk …
Sponsor: NRG Oncology
NCT ID: NCT05946213
Sites in Wisconsin: - Aspirus Cancer Care-Antigo-Volm Cancer Center — Antigo, Wisconsin
- Duluth Clinic Ashland — Ashland, Wisconsin
- Northwest Wisconsin Cancer Center — Ashland, Wisconsin
- Aurora Cancer Care-Southern Lakes VLCC — Burlington, Wisconsin
- Aurora Health Care Germantown Health Center — Germantown, Wisconsin
Phase 3 Recruiting Network
This study is being done to answer the following question: can the chance of prostate cancer growing or spreading be lowered by adding a drug to the usual combination of drugs? This study would like to find out if this approach is better o…
Sponsor: Canadian Cancer Trials Group
NCT ID: NCT06592924
Sites in Wisconsin: - Duluth Clinic Ashland — Ashland, Wisconsin
- Northwest Wisconsin Cancer Center — Ashland, Wisconsin
- Marshfield Medical Center-EC Cancer Center — Eau Claire, Wisconsin
- Essentia Health-Hayward Clinic — Hayward, Wisconsin
- Tamarack Health Hayward Medical Center — Hayward, Wisconsin
Phase 3 Recruiting Network
This phase III trial compares the effect of adding carboplatin to the standard of care chemotherapy drug cabazitaxel versus cabazitaxel alone in treating prostate cancer that keeps growing even when the amount of testosterone in the body i…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT06470243
Sites in Wisconsin: - Cancer Center of Western Wisconsin — New Richmond, Wisconsin
Phase 3 Recruiting Industry
Researchers are looking for new ways to treat metastatic castration-resistant prostate cancer (mCRPC). Researchers have designed a study medicine called ifinatamab deruxtecan (also called I-DXd or MK-2400) to treat mCRPC. The goal of this …
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06925737
Sites in Wisconsin: - University Hospital and UW Health Clinics ( Site 0065) — Madison, Wisconsin
- Medical College of Wisconsin ( Site 0008) — Milwaukee, Wisconsin
Phase 3 Recruiting Industry
The purpose of this study is to determine whether \[225Ac\]Ac-PSMA-617 (AAA817), given for up to 6 cycles at a dose of 10 Megabecquerel (MBq) +/- 10%, plus androgen receptor pathway inhibitor (ARPI), improves the radiographic progression f…
Sponsor: Novartis Pharmaceuticals
NCT ID: NCT06855277
Sites in Wisconsin: - Medical College of Wisconsin — Milwaukee, Wisconsin
Phase 2, Phase 3 Recruiting Industry
This is a Phase II/III study. Patient population is adult participants with PSMA-positive mCRPC who had treatments with androgen receptor pathway inhibitor (ARPI) and taxane-based chemotherapy and progressed on or after \[177Lu\]Lu-PSMA ta…
Sponsor: Novartis Pharmaceuticals
NCT ID: NCT06780670
Sites in Wisconsin: - Medical College Of Wisconsin — Milwaukee, Wisconsin
Phase 3 Recruiting Industry
The aim for this study is to assess the diagnostic performance of 64Cu-SAR-bisPSMA PET to detect regional nodal metastases.
Sponsor: Clarity Pharmaceuticals Ltd
NCT ID: NCT06056830
Sites in Wisconsin: - University of Wisconsin — Madison, Wisconsin
Phase 1, Phase 2 Recruiting Industry
The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. Th…
Sponsor: PMV Pharmaceuticals, Inc
NCT ID: NCT04585750
Sites in Wisconsin: - University of Wisconsin Carbone Cancer Center — Madison, Wisconsin
Phase 1, Phase 2 Recruiting Industry
The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic solid tumors or in participants with familial adenomatous polyposis (FAP).
Sponsor: Parabilis Medicines, Inc.
NCT ID: NCT05919264
Sites in Wisconsin: - University of Wisconsin, Carbone Cancer Center — Madison, Wisconsin
Phase 2 Recruiting Industry
The primary purpose of this study is to evaluate the safety, tolerability, and efficacy of SYNC-T Therapy SV-102 and to identify the maximum tolerated dose (MTD) and/or selected dose for phase 2b study.
Sponsor: Syncromune, Inc.
NCT ID: NCT06533644
Sites in Wisconsin: - Medical College of Wisconsin — Milwaukee, Wisconsin
Phase 2 Recruiting Federal
This is an unblinded, randomized clinical study comparing the efficacy of DNA damaging chemotherapy using carboplatin, to standard of care therapy for patients who have metastatic castrate resistant prostate cancer. This trial will use ola…
Sponsor: VA Office of Research and Development
NCT ID: NCT04038502
Sites in Wisconsin: - William S. Middleton Memorial Veterans Hospital, Madison, WI — Madison, Wisconsin
Phase 2 Recruiting Federal
This study will determine whether the presence of DNA repair deficiency in the form of alterations in the genes ATM, CDK12 or CHEK2 predicts for a high likelihood of responding to the use of intermittent high dose testosterone. This therap…
Sponsor: VA Office of Research and Development
NCT ID: NCT05011383
Sites in Wisconsin: - William S. Middleton Memorial Veterans Hospital, Madison, WI — Madison, Wisconsin
Phase 1, Phase 2 Recruiting Industry
This study is researching an investigational drug called REGN4336 both alone or together with another investigational drug called REGN5678. The study is focused on participants with previously treated metastatic prostate cancer. The main p…
Sponsor: Regeneron Pharmaceuticals
NCT ID: NCT05125016
Sites in Wisconsin: - Medical College of Wisconsin — Milwaukee, Wisconsin
Phase 2 Recruiting NIH
This phase II trial studies how well lutetium Lu 177 dotatate works in treating patients with prostate cancer with neuroendocrine differentiation that has spread to other places in the body (metastatic). Neuroendocrine differentiation refe…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05691465
Sites in Wisconsin: - University of Wisconsin Carbone Cancer Center - Eastpark Medical Center — Madison, Wisconsin
- University of Wisconsin Carbone Cancer Center - University Hospital — Madison, Wisconsin
Phase 2 Recruiting Industry
Hormone therapy, or androgen deprivation therapy (ADT) is a standard way to treat prostate cancer. It works by reducing the amount of the main male sex hormone, testosterone in the body. Androgen receptor pathway inhibitors (ARPIs) are ano…
Sponsor: Astellas Pharma Global Development, Inc.
NCT ID: NCT07005154
Sites in Wisconsin: - UW Health Carbone Cancer Center — Madison, Wisconsin
Phase 2 Recruiting Academic/Other
The purpose of this study is to find out whether talazoparib in combination with enzalutamide or talazoparib alone delays cancer progression in people with metastatic castration-resistant prostate cancer (mCRPC) who have homologous recombi…
Sponsor: Prostate Cancer Clinical Trials Consortium
NCT ID: NCT06844383
Sites in Wisconsin: - University of Wisconsin Carbone Cancer Center-Madison — Madison, Wisconsin
Phase 2 Recruiting Academic/Other
The goal of this clinical trial is to gain more information about how FAPI (fibroblast activation protein inhibitor) binds to certain type of cells in the tumor tissue. The main question it aims to answer is how this information can be use…
Sponsor: University of Wisconsin, Madison
NCT ID: NCT06675357
Sites in Wisconsin: - University of Wisconsin — Madison, Wisconsin
Phase 2 Recruiting Academic/Other
This is a multi-center single arm phase II study to evaluate the antitumor activity of zanzalintinib 60mg orally (PO) once daily in subjects with AVPC. Zanzalintinib may continue until radiographic progression (or beyond), intolerable adve…
Sponsor: Deepak Kilari
NCT ID: NCT07218666
Sites in Wisconsin: - Froedtert and The Medical College of Wisconsin — Milwaukee, Wisconsin
Phase 2 Recruiting Academic/Other
This is a single-arm, open-label phase 2 study to evaluate the role of pacritinib for patients with metastatic castrate-resistant prostate cancer that have progressed on ARSI. Patients will receive pacritinib 200 mg twice daily. To be elig…
Sponsor: Medical College of Wisconsin
NCT ID: NCT07226713
Sites in Wisconsin: - Froedtert & the Medical College of Wisconsin — Milwaukee, Wisconsin
Phase 1 Recruiting Industry
This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect of biomarkers of zanzalintinib administered alon…
Sponsor: Exelixis
NCT ID: NCT05176483
Sites in Wisconsin: - Exelixis Clinical Site #33 — Milwaukee, Wisconsin
Phase 1 Recruiting Industry
Study K36-MCRPC-001 is the first in human clinical trial testing KTX-2001 alone and with darolutamide in men with metastatic castration-resistant prostate cancer. The study aims to assess whether the drug is safe, increasing doses alone an…
Sponsor: K36 Therapeutics, Inc.
NCT ID: NCT07103018
Sites in Wisconsin: - University of Wisconsin — Madison, Wisconsin
Phase 1 Recruiting Industry
Study QXL138AM-001 is a Phase 1a/1b study to investigate the safety, pharmacokinetics, and preliminary activity of QXL138AM in subjects with locally advanced un-resectable and/or metastatic solid tumors and multiple myeloma. The study is a…
Sponsor: Nammi Therapeutics Inc
NCT ID: NCT06582017
Sites in Wisconsin: - Froedtert Hospital & the Medical College of Wisconsin — Milwaukee, Wisconsin
Phase 1 Recruiting Industry
This study will assess the safety and tolerability of valemetostat in combination with darolutamide in participants with Metastatic Castration Resistant Prostate Cancer (mCRPC).
Sponsor: Daiichi Sankyo
NCT ID: NCT07244341
Sites in Wisconsin: - Medical College Of Wisconsin — Milwaukee, Wisconsin
Phase 1 Recruiting Industry
The primary objectives of this study are to evaluate the safety and tolerability of xaluritamig administered as monotherapy or in combination with an oral Gonadotropin-releasing Hormone (GnRH) antagonist in the neoadjuvant setting followed…
Sponsor: Amgen
NCT ID: NCT06613100
Sites in Wisconsin: - Medical College of Wisconsin — Milwaukee, Wisconsin
Phase 1 Recruiting Industry
TITLE: Phase 1 First in Human Trial to Assess Safety and Tolerability of the Novel ACK1 Inhibitor (R)-9bMS in Patients with Prostate Cancer (PHAROS) STUDY DESCRIPTION: Prostate cancer (PC) patients receive androgen deprivation therapy (ADT…
Sponsor: TechnoGenesys, Inc.
NCT ID: NCT06705686
Sites in Wisconsin: - University of Wisconsin Carbone Cancer Center (UWCCC) - Cancer Connect — Madison, Wisconsin